Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA Trial

被引：78

作者：

Apter, Dan ^{[1
]}

Wheeler, Cosette M. ^{[2
,3
]}

Paavonen, Jorma ^{[4
]}

Castellsague, Xavier ^{[5
]}

Garland, Suzanne M. ^{[6
,7
]}

Skinner, S. Rachel ^{[8
,9
]}

Naud, Paulo ^{[10
]}

Salmeron, Jorge ^{[11
,12
]}

Chow, Song-Nan ^{[13
]}

Kitchener, Henry C. ^{[14
]}

Teixeira, Julio C. ^{[15
]}

Jaisamram, Unnop ^{[16
]}

Limson, Genara ^{[17
]}

Szarewski, Anne ^{[18
]}

Romanowski, Barbara ^{[19
]}

Aoki, Fred Y. ^{[20
]}

Schwarz, Tino F. ^{[21
,22
]}

Poppe, Willy A. J. ^{[23
]}

Xavier Bosch, F. ^{[24
]}

Mindel, Adrian ^{[25
]}

De Sutter, Philippe

Hardt, Karin ^{[26
,27
]}

Zahaf, Toufik ^{[26
,27
]}

Descamps, Dominique ^{[26
,27
]}

Struyf, Frank ^{[26
,27
]}

Lehtinen, Matti ^{[28
]}

Dubin, Gary ^{[29
]}

机构：

[1] Sexual Hlth Clin, Family Federat Finland, Helsinki, Finland

[2] Univ New Mexico, Hlth Sci Ctr, Dept Pathol, Albuquerque, NM 87131 USA

[3] Univ New Mexico, Hlth Sci Ctr, Dept Obstet & Gynecol, Albuquerque, NM 87131 USA

[4] Univ Helsinki, Dept Obstet & Ginecol, Helsinki, Finland

[5] Hosp Llobregat, Biomed Res Ctr Network Epidemiol & Publ Hlth CIBE, DIBELL, ICO,Canc Epidemiol Res Program, Catalonia, Spain

[6] Univ Melbourne, Royal Womens Hosp, Murdoch Childrens Res Inst, Microbiol & Infect Dis Dept, Melbourne, Vic, Australia

[7] Univ Melbourne, Murdoch Childrens Res Inst, Dept Obstet & Gynaecol, Melbourne, Vic, Australia

[8] Telethon Inst Child Hlth Res, Vaccine Trials Grp, Perth, WA, Australia

[9] Univ Sydney, Childrens Hosp Westmead, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia

[10] Univ Fed Rio Grande do Sul, Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil

[11] Inst Mexicano Seguro Social, Unidad Invest Epidemiol, Cuernavaca, Morelos, Mexico

[12] Inst Mexicano Seguro Social, Serv Salud, Cuernavaca, Morelos, Mexico

[13] Natl Taiwan Univ, Coll Med & Hosp, Dept Obstet & Gynecol, Taipei 10764, Taiwan

[14] St Marys Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 0JH, Lancs, England

[15] Univ Estadual Campinas, Campinas, SP, Brazil

[16] Chulalongkorn Univ, Fac Med, Dept Obstet & Gynaecol, Bangkok 10330, Thailand

[17] Univ Philippines, Philippine Gen Hosp, Coll Med, Makati Med Ctr, Makati, Philippines

[18] Queen Mary Univ London, Ctr Canc Prevent, Wolfson Inst Prevent Med, London, England

[19] Univ Alberta, Edmonton, AB, Canada

[20] Univ Manitoba, Winnipeg, MB, Canada

[21] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Cent Lab, Wurzburg, Germany

[22] Univ Wurzburg, Acad Teaching Hosp, Stiftung Juliusspital, Vaccinat Ctr, Wurzburg, Germany

[23] Univ Hosp KU Leuven Gasthuisberg, Dept Gynaecol, Leuven, Belgium

[24] Network Cooperat Canc Res RTICC, Inst Catala Oncol, IDIBELL, Canc Epidemiol Res Program, Catalonia, Spain

[25] Ctr AIDS Programme Res Soth Africa, Durban, South Africa

[26] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Afdelingshoofd Gynaecol Oncol, Brussels, Belgium

[27] GSK Vaccines, Wavre, Belgium

[28] Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland

[29] GSK Vaccines, King Of Prussia, PA USA

来源：

CLINICAL AND VACCINE IMMUNOLOGY | 2015年 / 22卷 / 04期

关键词：

OF-STUDY ANALYSIS; PARTICLE VACCINE; HPV-VACCINATION; FOLLOW-UP; TYPE-16; CANCER; PREVALENCE; SAFETY; IMMUNIZATION; PREVENTION;

D O I：

10.1128/CVI.00591-14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults (PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose (vaccine, n = 9,319; control, n = 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine, n = 5,822; control, n = 5,819) had no evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs. Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithelial neoplasia grade 1 or greater (CIN1+), CIN2+, and CIN3+ associated with HPV-16/18 was 55.5% (96.1% confidence interval [CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% (-1.1, 56.9). VE against CIN1+, CIN2+, and CIN3+ irrespective of HPV DNA was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1+, CIN2+, and CIN3+ associated with HPV-16/ 18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPV DNA it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18 was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up to 18 years of age is most likely effective.

引用

页码：361 / 373

页数：13

共 50 条

[1] Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
Paovonen, J.
Naud, P.
Salmeron, J.
Wheeler, C. M.
Chow, S-N
Apter, D.
Kitchener, H.
Castellsague, X.
Teixeira, J. C.
Skinner, S. R.
Hedrick, J.
Jaisamrarn, U.
Limson, G.
Garland, S.
Szarewski, A.
Romanowski, B.
Aoki, F. Y.
Schwarz, T. F.
Poppe, W. A. J.
Bosch, F. X.
Jenkins, D.
Hardt, K.
Zahaf, T.
Descamps, D.
Struyf, F.
Lehtinen, M.
Dubin, G.
[J]. LANCET, 2009, 374 (9686): : 301 - 314
[2] Efficacy of the HPV-16/18 AS04-Adjuvanted Vaccine Against Low-Risk HPV Types (PATRICIA Randomized Trial): An Unexpected Observation
Szarewski, Anne
Skinner, S. Rachel
Garland, Suzanne M.
Romanowski, Barbara
Schwarz, Tino F.
Apter, Dan
Chow, Song-Nan
Paavonen, Jorma
Del Rosario-Raymundo, M. Rowena
Teixeira, Julio C.
De Carvalho, Newton S.
Castro-Sanchez, Maria
Castellsague, Xavier
Poppe, Willy A. J.
De Sutter, Philippe
Huh, Warner
Chatterjee, Archana
Tjalma, Wiebren A.
Ackerman, Ronald T.
Martens, Mark
Papp, Kim A.
Bajo-Arenas, Jose
Harper, Diane M.
Torne, Aureli
David, Marie-Pierre
Struyf, Frank
Lehtinen, Matti
Dubin, Gary
[J]. JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (09): : 1391 - 1396
[3] Efficacy of human papillomavirus (HPV)-16/18AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women (vol 374, pg 301, 2009)
Paavonen, J.
[J]. LANCET, 2010, 376 (9746): : 1054 - 1054
[4] Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Wheeler, Cosette M.
Castellsague, Xavier
Garland, Suzanne M.
Szarewski, Anne
Paavonen, Jorma
Naud, Paulo
Salmeron, Jorge
Chow, Song-Nan
Apter, Dan
Kitchener, Henry
Teixeira, Julio C.
Skinner, S. Rachel
Jaisamrarn, Unnop
Limson, Genara
Romanowski, Barbara
Aoki, Fred Y.
Schwarz, Tino F.
Poppe, Willy A. J.
Xavier Bosch, F.
Harper, Diane M.
Huh, Warner
Hardt, Karin
Zahaf, Toufi K.
Descamps, Dominique
Struyf, Frank
Dubin, Gary
Lehtinen, Matti
[J]. LANCET ONCOLOGY, 2012, 13 (01): : 100 - 110
[5] Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled trial
Hu, Shangying
Xu, Xiaoqian
Zhu, Fengcai
Hong, Ying
Hu, Yuemei
Zhang, Xun
Pan, Qinjing
Zhang, Wenhua
Zhang, Chengfu
Yang, Xiaoping
Yu, Jiaxi
Zhu, Jiahong
Zhu, Yejiang
Chen, Feng
Zhao, Shuang
Karkada, Naveen
Tang, Haiwen
Bi, Dan
Struyf, Frank
Zhao, Fanghui
[J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (04) : 955 - 964
[6] HPV-16/18 AS04-adjuvanted vaccine prevented cervical intraepithelial neoplasia ≥ grade 3 in young women
Budenholzer, Brian
[J]. ANNALS OF INTERNAL MEDICINE, 2012, 157 (02)
[7] Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
Lehtinen, Matti
Paavonen, Jorma
Wheeler, Cosette M.
Jaisamrarn, Unnop
Garland, Suzanne M.
Castellsague, Xavier
Skinner, S. Rachel
Apter, Dan
Naud, Paulo
Salmeron, Jorge
Chow, Song-Nan
Kitchener, Henry
Teixeira, Julio C.
Hedrick, James
Limson, Genara
Szarewski, Anne
Romanowski, Barbara
Aoki, Fred Y.
Schwarz, Tino F.
Poppe, Willy A. J.
De Carvalho, Newton S.
Germar, Maria Julieta V.
Peters, Klaus
Mindel, Adrian
De Sutter, Philippe
Xavier Bosch, F.
David, Marie-Pierre
Descamps, Dominique
Struyf, Frank
Dubin, Gary
[J]. LANCET ONCOLOGY, 2012, 13 (01): : 89 - 99
[8] Safety and Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine: A Randomized, Controlled Trial in Adolescent Girls
Medina, Doris M. Rivera
Valencia, Alejandra
de Velasquez, Alet
Huang, Li-Min
Prymula, Roman
Garcia-Sicilia, Jose
Rombo, Lars
David, Marie Pierre P.
Descamps, Dominique
Hardt, Karin
Dubin, Gary
[J]. JOURNAL OF ADOLESCENT HEALTH, 2010, 46 (05) : 414 - 421
[9] Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18
Szarewski, A.
Poppe, W. A. J.
Skinner, S. R.
Wheeler, C. M.
Paavonen, J.
Naud, P.
Salmeron, J.
Chow, S-N.
Apter, D.
Kitchener, H.
Castellsague, X.
Teixeira, J. C.
Hedrick, J.
Jaisamrarn, U.
Limson, G.
Garland, S.
Romanowski, B.
Aoki, F. Y.
Schwarz, T. F.
Bosch, F. X.
Harper, D. M.
Hardt, K.
Zahaf, T.
Descamps, D.
Struyf, F.
Lehtinen, M.
Dubin, G.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (01) : 106 - 116
[10] Efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine in Chinese women aged 18-25years: event-triggered analysis of a randomized controlled trial
Zhu, Feng-cai
Hu, Shang-Ying
Hong, Ying
Hu, Yue-Mei
Zhang, Xun
Zhang, Yi-Ju
Pan, Qin-Jing
Zhang, Wen-Hua
Zhao, Fang-Hui
Zhang, Cheng-Fu
Yang, Xiaoping
Yu, Jia-Xi
Zhu, Jiahong
Zhu, Yejiang
Chen, Feng
Zhang, Qian
Wang, Hong
Wang, Changrong
Bi, Jun
Xue, Shiyin
Shen, Lingling
Zhang, Yan-Shu
He, Yunkun
Tang, Haiwen
Karkada, Naveen
Suryakiran, Pemmaraju
Bi, Dan
Struyf, Frank
[J]. CANCER MEDICINE, 2017, 6 (01): : 12 - 25

← 1 2 3 4 5 →